Edward Rudnic

Ed Rudnic has been in the biotech industry for over 15 years. Ed has held various positions, but most recently they are the COO and head of Research & Development at Maxwell Biosciences. Prior to that, they were the President and CEO of DisperSol Technologies from October 2016 to April 2022. At DisperSol, Rudnic was responsible for developing five clinical programs, one of which is in Phase II and another in Phase III. Ed left DisperSol after the board decided to move back to a CDMO model and out license the lead clinical assets. From November 2015 to October 2016, Rudnic was the Chairman and CEO of Vivreon Biosciences. There they were responsible for advising a small start-up biotech on raising capital and securing grants for NCE development in Alzheimer's disease and other neurodegenerative diseases. Ed was able to secure almost $2MM in NIH SBIR and Alzheimer's Drug Development Foundation grants for the company before resigning from both positions in October 2016 to engage as the CEO and Director of DisperSol Technologies.

Ed Rudnic has a Ph.D. in Pharmaceutics from the University of Rhode Island, a Master of Science in Pharmaceutics from the University of Rhode Island, and a Bachelor of Science (B.S.) in Pharmacy from the University of Rhode Island.

Some of their coworkers include Mira Sirotic - Director, Investor Relations, Sheetal Vali - Senior Director, Drug Development, and Kent Kirshenbaum - Chief Scientific Officer. A direct report to Ed Rudnic is and Meagan Stone - Senior Director, Operations. Their manager is Joshua McClure, CEO.